Search

Theranostic polymeric nanomaterials are of special important in cancer treatment. Here, novel galactose targeted pH-responsive amphiphilic multiblock copolymer conjugated with both drug and near-infrared fluorescence (NIR) probe has been designed and prepared by a four-steps process: (1) ring-opening polymerization (ROP) of N-carboxy anhydride (NCA) monomers using propargylamine as initiator; (2) reversible addition-fragmentation chain transfer (RAFT) polymerization of oligo(ethylene glycol) methacrylate (OEGMA) and gal monomer by an azido modified RAFT agent; (3) combing the obtained two polymeric segments by click reaction; (4) NIR copolymer prodrug was synthesized by chemical linkage of both cyanine dye and anticancer drug doxorubicin to the block copolymer via amide bond and hydrazone, respectively. The obtained NIRF copolymers were characterized by nuclear magnetic resonance (NMR), gel permeation chromatography (GPC), and its was measured by means of micelles dynamic light scattering (DLS), field emission transmission electron microscopy (FETEM), and UV-vis and fluorescence spectrophotometry. The prodrug has strong fluorescence in the near-infrared region, and a pH sensitive drug release was confirmed at pH of 5.4 via an in vitro drug release experiment. Confocal laser scanning microscopy (CLSM) and flow cytometry experiments of the prodrug on both HepG2 and NIH3T3 cells reveal that the galactose targeted polymeric prodrug shows a fast and enhanced endocytosis due to the specific interaction for HepG2 cells, indicating the as-prepared polymer is a candidate for theranosis of liver cancer.

Drug nanocrystals, one of most common drug delivery systems, enable the delivery of poorly water-soluble drugs with high drug loading and enhanced dissolution. The rapid clearance and uncontrolled drug release of drug nanocrystals limit their delivery efficiency and clinical application. Herein, an amphiphilic co-polymer, poly oligo(ethylene glycol) methacrylate-b-poly(styrene–co-4-formylphenyl methacrylate) (POEGMA-b-P (St-co-FPMA), PPP), characterized by a hydrophilic part with bottlebrush-like oligo(ethylene glycol) methacrylate (OEGMA) side chains, was synthesized as stabilizers to fabricate a high-drug-loading nanocrystal micelle (053-PPP NC micelle) using the chronic myeloid leukemia (CML) drug candidate N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053 or 053) as a model drug. The 053-PPP NC micelle was characterized and subjected to in vitro and in vivo studies. It featured a worm-like shape of small size, high drug loading (~50%), high colloidal stability, and controlled release in vitro. The presence of the 053-PPP NC micelle resulted in a long-circulation property and a much higher AUC. The 053-PPP NC micelle induced higher accumulation in the tumor tissues under multiple continuous administration. For in vivo efficacy, the 053-PPP NC micelle with a longer dosing interval (96 h), beneficial for improving patient adherence, demonstrated superiority to the 053-F127 NC. The proposed stabilizer PPP and the 053-PPP NC micelle with high drug loading enables drug delivery with long circulation and controlled release of drugs. It is also promising for the development of more efficient nanocrystal-based intravenous injection formulations for poorly water-soluble drugs. It might also offer new possibilities for potential clinical application of the CML candidate drug 053. [ABSTRACT FROM AUTHOR]

[Display omitted] Nanocrystals (NCs) enable the delivery of poorly water-soluble drugs with improved dissolution and bioavailability. However, their uncontrolled release and instability make targeted delivery challenging. Herein, a nano-in-nano delivery system composed of a drug nanocrystal core and liposome shell (NC@Lipo) is presented, which merges the advantages of drug nanocrystals (high drug loading) and liposomes (easy surface functionalization and high stability) for targeted delivery of hydrophobic drugs to tumors. CHMFL-ABL-053 (053), a hydrophobic drug candidate discovered by our group, was employed as a model drug to demonstrate the performance of NC@Lipo delivery system. Surface PEGylated (053-NC@PEG-Lipo) and folic acid-functionalized (053-NC@FA-Lipo) formulations were fabricated by wet ball milling combined with probe sonication. 053-NC@Lipo enabled high drug loading (up to 19.51%), considerably better colloidal stability, and longer circulation in vivo than 053-NC. Compared with free 053, 053-NC@PEG-Lipo and 053-NC@FA-Lipo exhibited higher tumor accumulation and considerably better in vivo antitumor efficacy in K562 xenograft mice with tumor growth inhibition rate (TGI) of up to 98%. Additionally, more effective tumor cell targeting in vitro and higher TGI in vivo were achieved with 053-NC@FA-Lipo. The NC@Lipo strategy may contribute to the targeted delivery of poorly water-soluble drugs with high drug loading, high stability, and tailorable surface, and has potential for the development of more efficient nanocrystal- and liposome-based formulations for commercial and clinical applications. It may also provide new opportunities for potential clinical application of candidate 053. [ABSTRACT FROM AUTHOR]